Mar 22, 2021 10:38 JST

Source: Eisai

Eisai Awarded The New Diversity Management Selection 100

TOKYO, Mar 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program.

METI has been presenting a METI Minister's Award under the New Diversity Management Selection 100 Program since its inauguration in FY 2012 with the aim of widely introducing the advanced efforts of companies that link diversity promotion to management results and encouraging companies to engage in diversity management. In the FY2020 award, among the priority themes of the New Diversity Management Selection 100 Program, Eisai received a particularly high evaluation for items such as activities promoting participation of diverse employees including women and employees with foreign nationalities, realizing diverse career paths for employees, and implementing workstyle innovation and management strategy transformation, and so on.

Eisai defines its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. Eisai believes that, in order to realize the hhc philosophy, it is important for each Eisai employee to firstly get close to patients, see the situation from their perspectives in order to learn to empathize with thoughts and feelings that might not necessarily always be expressed in words. The hhc philosophy pervades the awareness of each and every employee of the Eisai Group and is put into practice in our daily work. Eisai is working on the Diversity & Inclusion as a management strategy to sustainably realize the hhc philosophy no matter how the social environment changes. Eisai has been promoting its initiatives to support the active participation of diverse employees such as women and employees with foreign nationalities, by improving environments surrounding employees, reforming workstyles, and changing the mindset of all employees. In addition, Eisai is enhancing to develop human resources across Eisai Group worldwide, such as the programs designed for developing global leaders that Eisai has continuously promoted for many years.

Eisai continues to promote the Diversity & Inclusion Strategy in order to response to the diversifying needs of patients, their families, and consumers and to realize the hhc philosophy.

* For more information on Eisai's Strategy for Talents Innovation, including its initiatives toward diversity at Eisai, please see Eisai Integrated Report. https://www.eisai.com/ir/library/annual/index.html

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai and National Cancer Center Commence Joint Research and Development Project
May 14 2021 16:48 JST
 
Eisai's Statement of Commitment for Carbon Neutrality by 2040
May 11 2021 09:00 JST
 
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
May 07 2021 10:08 JST
 
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
April 28 2021 11:33 JST
 
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
April 23 2021 13:55 JST
 
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
April 23 2021 12:02 JST
 
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
April 23 2021 08:07 JST
 
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
April 20 2021 08:23 JST
 
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
 
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
 
More Press release >>

Latest Press Release


More Latest Release >>